Who
Thomas R. Staab II
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Tenax Therapeutics; Chief Financial Officer, Lensar; Senior Vice President and CFO, BioCryst Pharmaceuticals; EVP, CFO & Treasurer, Inspire Pharmaceuticals.
In numbers
- Trades disclosed
- 289
- Buys
- 3
- Sells
- 46
- Bought
- $31K
- Sold
- $2.4M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 19 Jan 2006
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K5,675 at $1.94 | filing |
| 11 Sep 2026filed 15 Sep 2026 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K5,675 at $1.94 | filing |
| 11 May 2026filed 13 May 2026 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | TENX Tenax Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | TENX Tenax TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $7,2701,350 at $5.39 | filing |
| 6 May 2026filed 8 May 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $7,2771,350 at $5.39 | filing |
| 19 Mar 2026filed 19 Mar 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code M | $15K5,500 at $2.65 | filing |
| 19 Mar 2026filed 19 Mar 2026 | LNSR Lensaroption or derivative · Medical Devices | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | LNSR Lensaroption or derivative · Medical Devices | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code M | $15K5,500 at $2.65 | filing |
| 18 Feb 2026filed 20 Feb 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $12K1,076 at $11.32 | filing |
| 18 Feb 2026filed 20 Feb 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $12K1,076 at $11.32 | filing |
| 11 Jan 2026filed 13 Jan 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $21K1,826 at $11.57 | filing |
| 11 Jan 2026filed 13 Jan 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $21K1,826 at $11.57 | filing |
| 18 Feb 2025filed 20 Feb 2025 | LNSR LensarMedical Devices | SEC FORM 4 Code A | —12,766 at $0.00 | filing |
| 11 Jan 2025filed 6 Feb 2025 | LNSR LensarMedical Devices | SEC FORM 4 Code F | $15K1,839 at $8.25 | filing |
| 8 Aug 2024filed 12 Aug 2024 | LNSR Lensaroption or derivative · Medical Devices | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 8 Aug 2024filed 12 Aug 2024 | LNSR LensarMedical Devices | SEC FORM 4 Code M | $9,2753,500 at $2.65 | filing |
News
Tenax Therapeutics (NASDAQ:TENX) Stock: Insider Adar1 Capital Management, Llc Acquires 336,528 SharesTENX · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Thomas R. Staab II; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.